{"nctId":"NCT00253422","briefTitle":"Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors","startDateStruct":{"date":"2004-03-26","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":698,"armGroups":[{"label":"Faslodex + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anastrozole","Drug: Fulvestrant"]},{"label":"Faslodex + Arimidex","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anastrozole","Drug: Fulvestrant"]},{"label":"Exemestane","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Exemestane"]}],"interventions":[{"name":"Anastrozole","otherNames":["Arimidex (or placebo)"]},{"name":"Exemestane","otherNames":[]},{"name":"Fulvestrant","otherNames":["Faslodex"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n\n  * Locally advanced or metastatic disease\n* Metastatic disease must be measurable or evaluable\n\n  * Patients with bone only metastases are eligible provided there is an evaluable site of bone metastasis that can be followed by x-ray, MRI, or CT scan\n* Relapsed or progressed during prior treatment with single-agent nonsteroidal aromatase inhibitor (NSAI)\\*, meeting either of the following criteria:\n\n  * NSAI given as adjuvant therapy that lasted ≥ 12 months\n  * Achieved an objective complete response, partial response, or stable disease that lasted ≥ 6 months after prior first-line therapy with NSAI for locally advanced or metastatic disease\n\n    * Chemotherapy as part of the first-line therapy given before initiation of NSAI allowed NOTE: \\*Patients are required to continue to take NSAI until beginning of study treatment.\n* No rapidly progressive visceral disease (i.e., lymphangitis carcinomatosa or diffuse hepatic involvement)\n* Hormone receptor status:\n\n  * Estrogen receptor (ER) and/or progesterone receptor positive tumor\n  * No ER-unknown disease\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, as defined by 1 of the following criteria:\n\n  * Age 60 and over\n  * Age 45 to 59 AND ≥ 12 months since last menstrual period with no prior hysterectomy\n  * Any age with prior bilateral oophorectomy\n\nPerformance status\n\n* WHO 0-2\n\nLife expectancy\n\n* More than 3 months\n\nHematopoietic\n\n* Neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n\n  * No thrombocytopenia\n* Hemoglobin ≥ 10 g/dL\n\nHepatic\n\n* AST and ALT ≤ 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase ≤ 5 times ULN (unless due to bone metastases)\n* No liver disease\n\nRenal\n\n* Creatinine \\< 1.97 mg/dL\n\nOther\n\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* See Disease Characteristics\n* Prior neoadjuvant or adjuvant chemotherapy allowed\n\nEndocrine therapy\n\n* See Disease Characteristics\n* Prior tamoxifen as neoadjuvant or adjuvant therapy allowed\n* No systemic corticosteroids that lasted \\> 15 days within the past 4 weeks\n\nOther\n\n* More than 4 weeks since prior investigational drugs\n* Concurrent bisphosphonates for bone metastases allowed provided bisphosphonate therapy has been established for ≥ 6 months\n\n  * Concurrent initiation of bisphosphonate allowed provided patient has soft tissue or visceral metastases as the measurable or evaluable target lesion\n* No concurrent anticoagulant therapy\n* No concurrent unlicensed noncancer investigational agents","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"defined as time from randomisation to progression of existing disease, new sites of disease, second primary cancer if change in systemic treatment was necessary, or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.1","spread":null},{"groupId":"OG002","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"The proportion of patients identified as having a complete response (CR) or partial response (PR) at any time whilst on study treatment. Response is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as either disappearance of all lesions or a \\>=30% decrease in the sum of the longest diameter of target lesions with no progressing non-target lesions and no new lesions. Objective Response (OR) = CR + PR","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"time from first assessment of response to progression or death. Response is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as either disappearance of all lesions or a \\>=30% decrease in the sum of the longest diameter of target lesions with no progressing non-target lesions and no new lesions. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"12.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Benefit Rate","description":"Complete or partial response or stable disease for at least six months prior to progression. Response is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as either disappearance of all lesions or a \\>=30% decrease in the sum of the longest diameter of target lesions with no progressing non-target lesions and no new lesions. Stable disease is neither responding or progressing. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Clinical Benefit","description":"Time from first assessment of clinical benefit to progression or death. Response is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as either disappearance of all lesions or a \\>=30% decrease in the sum of the longest diameter of target lesions with no progressing non-target lesions and no new lesions. Stable disease is neither responding or progressing. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Clinical benefit = (CR+PR)+(SD\\>=6months).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from randomisation until death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null},{"groupId":"OG001","value":"20.2","spread":null},{"groupId":"OG002","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability of Treatment","description":"To evaluate the overall safety and tolerability. The number of patients experiencing at least one adverse event. Refer to adverse event section for more details.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"227","spread":null},{"groupId":"OG002","value":"230","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":225},"commonTop":["Lethargy","Arthralgia","Vomiting","Hot Flush","Insomnia"]}}}